Subsequent Chemotherapy Improves Survival Outcome in Advanced Non–Small-Cell Lung Cancer With Acquired Tyrosine Kinase Inhibitor Resistance

Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, 353, 123, 10.1056/NEJMoa050753

Hsieh, 2006, Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer, Lung Cancer, 53, 311, 10.1016/j.lungcan.2006.06.005

Tsao, 2005, Erlotinib in lung cancer - molecular and clinical predictors of outcome, N Engl J Med, 353, 133, 10.1056/NEJMoa050736

Mok, 2008, Phase III, randomised, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) (IPASS), Ann Oncol, 19, viii1

Kris, 2003, Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial, JAMA, 290, 2149, 10.1001/jama.290.16.2149

Perez-Soler, 2004, Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer, J Clin Oncol, 22, 3238, 10.1200/JCO.2004.11.057

Godin-Heymann, 2007, Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation, Cancer Res, 67, 7319, 10.1158/0008-5472.CAN-06-4625

Haber, 2005, Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class, Cell Cycle, 4, 1057, 10.4161/cc.4.8.1874

Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478

Riely, 2007, Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus, Clin Cancer Res, 13, 5150, 10.1158/1078-0432.CCR-07-0560

Blay, 2007, Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group, J Clin Oncol, 25, 1107, 10.1200/JCO.2006.09.0183

Chen, 2005, Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study, J Chemother, 17, 679, 10.1179/joc.2005.17.6.679

Yang, 2006, Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer, Cancer, 107, 1873, 10.1002/cncr.22220

Fukuoka, 2003, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] [Erratum appears in: J Clin Oncol 2004; 22:4811], J Clin Oncol, 21, 2237, 10.1200/JCO.2003.10.038

Engelman, 2006, Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer, J Clin Invest, 116, 2695, 10.1172/JCI28656

Kwak, 2005, Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib, Proc Natl Acad Sci U S A, 102, 7665, 10.1073/pnas.0502860102

Li, 2008, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models, Oncogene, 27, 4702, 10.1038/onc.2008.109

Tang, 2008, Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer, Br J Cancer, 99, 911, 10.1038/sj.bjc.6604559

Shi, 2007, Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance, Cancer Res, 67, 11012, 10.1158/0008-5472.CAN-07-2686

Yang, 2005, Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein, Cancer Res, 65, 6943, 10.1158/0008-5472.CAN-05-0641

Usuda, 2007, Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a “never-smoked” female patient with advanced non-small cell lung cancer, Lung Cancer, 58, 296, 10.1016/j.lungcan.2007.05.019

Giaccone, 2004, Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1, J Clin Oncol, 22, 777, 10.1200/JCO.2004.08.001

Herbst, 2005, TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer, J Clin Oncol, 23, 5892, 10.1200/JCO.2005.02.840

Choe, 2007, Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck, Clin Cancer Res, 13, 3015, 10.1158/1078-0432.CCR-06-2959

Ciardiello, 2002, ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells, Int J Cancer, 98, 463, 10.1002/ijc.10230

Judde, 2007, Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response, Int J Cancer, 120, 1579, 10.1002/ijc.22364

Van Schaeybroeck, 2006, Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells, Mol Cancer Ther, 5, 1154, 10.1158/1535-7163.MCT-05-0446

Solit, 2005, Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel, Clin Cancer Res, 11, 1983, 10.1158/1078-0432.CCR-04-1347

Gandara, 2009, Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics, J Clin Oncol, 27, 3540, 10.1200/JCO.2008.20.8793

Wu, 2008, Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications, Cancer, 113, 3199, 10.1002/cncr.23925